Skip to content
The Nexus
DossierENTITY

KEYNOTE-942 study

Coverage of KEYNOTE-942 study in the Nexus archive.

Earliest in view: Jun 2 · 17:03 UTCMost recent: Jun 2 · 17:03 UTC
Co-mentioned in this coverage
intismeran autogenetopic1KEYTRUDAtopic1Merckorganization1Modernaorganization1American Society of Clinical Oncologyorganization1melanomatopic1pembrolizumabtopic1
Recent coverage
  • HEALTHJun 2 · 17:03 UTCFOX NEWS
    Could cancer vaccines be next? New treatment cuts melanoma risk by nearly 50%

    A new personalized mRNA cancer therapy, intismeran autogene, combined with KEYTRUDA, reduced melanoma recurrence or death risk by 49% over five years in a phase 2b study. The treatment, developed by Merck and Moderna, showed sustained benefits and a manageable safety profile in high-risk melanoma patients. It is now in phase 3 trials.